FDA授予阿西米尼加速批准用于新诊断的慢性髓性白血病
正文 · 中文译文
FDA授予阿西米尼加速批准用于新诊断的慢性髓性白血病 癌症批准 肿瘤(癌症)/血液系统恶性肿瘤批准通知 进行中 | 癌症加速批准 已验证临床获益 | 癌症加速批准 已撤回 | 癌症加速批准 其他 | 癌症加速批准 2024年10月29日,美国食品药品监督管理局(FDA)授予阿西米尼(Scemblix,诺华公司)加速批准,用于新诊断的费城染色体阳性慢性髓性白血病(Ph+ CML)慢性期(CP)成人患者。 Scemblix的完整处方信息将发布在Drugs@FDA上。 疗效与安全性 阿西米尼用于新诊断Ph+ CML慢性期的疗效在ASC4FIRST(NCT04971226)中进行了评估,该研究是一项多中心、随机、活性对照、开放标签试验。共405例患者按1:1随机分配接受阿西米尼或研究者选择的酪氨酸激酶抑制剂(IS-TKI)(伊马替尼、尼洛替尼、达沙替尼或博舒替尼)。主要疗效结局指标为48周时的主要分子学缓解(MMR)率。48周时,阿西米尼组的MMR率为68%(95% CI:61,74),IS-TKI组为49%(95% CI:42,56)(差异19% [95% CI:10,28],p值<0.001)。在伊马替尼分层内,阿西米尼组的MMR率为69%(95% CI:59,78),IS-TKI组为40%(95% CI:31,50)(差异30% [95% CI:17,42],p值<0.001)。 在新诊断和既往接受过治疗的慢性期(CP)费城染色体阳性(Ph+)慢性髓性白血病(CML)患者的汇总安全性人群中,最常见的不良反应(≥20%)为肌肉骨骼疼痛、皮疹、疲乏、上呼吸道感染、头痛、腹痛和腹泻。在新诊断的CP期Ph+ CML患者中,最常见的实验室异常(≥40%)为淋巴细胞计数降低、白细胞计数降低、血小板计数降低、中性粒细胞计数降低和校正钙降低。 asciminib的推荐剂量为80 mg口服每日一次,约在每日同一时间服用,或40 mg口服每日两次,约间隔12小时。 本审评根据Project Orbis开展,该项目是美国FDA肿瘤卓越中心的一项倡议。Project Orbis为国际合作伙伴之间肿瘤药物的同步提交和审评提供了框架。在本审评中,FDA与加拿大卫生部(HC)和瑞士瑞士药品监督管理局(SMC)合作。其他监管机构的申请审评仍在进行中。 加速审评程序 本审评采用了实时肿瘤审评(RTOR)试点项目,该项目简化了完整临床应用申报前的数据提交,并采用了评估辅助工具(Assessment Aid),这是申请人自愿提交以促进FDA评估的工具。FDA比FDA目标日期提前一个月批准了该申请。 本申请获得了优先审评、突破性疗法认定和孤儿药认定。FDA的加速审批程序在《行业指南:严重疾病药物和生物制品的加速审批程序》中有详细描述。 医疗保健专业人员应将所有怀疑与使用任何药物和器械相关的严重不良事件报告至FDA的MedWatch报告系统,或致电1-800-FDA-1088。 如需获取研究性肿瘤产品单患者IND方面的协助,医疗保健专业人员可联系OCE的Project Facilitate,电话240-402-0004,或发送电子邮件至OncProjectFacilitate@fda.hhs.gov。 在X上关注肿瘤卓越中心:@FDAOncology。 内容截至日期: 2024年10月29日 受监管产品 药物 肿瘤学
正文 · 英文原文
FDA grants accelerated approval to asciminib for newly diagnosed chronic myeloid leukemia Cancer Approvals Oncology (Cancer)/Hematologic Malignancies Approval Notifications Ongoing | Cancer Accelerated Approvals Verified Clinical Benefit | Cancer Accelerated Approvals Withdrawn | Cancer Accelerated Approvals Other | Cancer Accelerated Approvals On October 29, 2024, the Food and Drug Administration granted accelerated approval to asciminib (Scemblix, Novartis AG) for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). Full prescribing information for Scemblix will be posted on Drugs@FDA. Efficacy and Safety The efficacy of asciminib for newly diagnosed Ph+ CML in CP was evaluated in ASC4FIRST (NCT04971226), a multicenter, randomized, active-controlled, open-label trial. A total of 405 patients were randomized (1:1) to receive either asciminib or investigator-selected tyrosine kinase inhibitors (IS-TKIs) (imatinib, nilotinib, dasatinib, or bosutinib). The main efficacy outcome measure was major molecular response (MMR) rate at 48 weeks. The MMR rate at 48 weeks was 68% (95% CI: 61, 74) in the asciminib arm and 49% (95% CI: 42, 56) in the IS-TKIs arm (difference 19% [95% CI: 10, 28], p-value <0.001). Within the imatinib stratum, the MMR rate was 69% (95% CI: 59, 78) in the asciminib arm and 40% (95% CI: 31, 50) in the IS-TKIs arm (difference 30% [95% CI: 17, 42], p-value <0.001). In the pooled safety population in patients with newly diagnosed and previously treated Ph+ CML in CP, the most common adverse reactions (≥20%) were musculoskeletal pain, rash, fatigue, upper respiratory tract infection, headache, abdominal pain, and diarrhea. The most common laboratory abnormalities (≥40%) in patients with newly diagnosed Ph+ CML in CP were decreased lymphocyte count, decreased leukocyte count, decreased platelet count, decreased neutrophil count, and decreased calcium corrected. The recommended asciminib dosage is 80 mg taken orally once daily at approximately the same time of day or 40 mg taken orally twice daily at approximately 12-hour intervals. This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with Health Canada (HC) and Switzerland’s Swissmedic (SMC). The application reviews are ongoing at the other regulatory agencies. Expedited Programs This review used the Real-Time Oncology Review (RTOR) pilot program, which streamlined data submission prior to the filing of the entire clinical application, and the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment. The FDA approved this application one month ahead of the FDA goal date. This application was granted priority review, breakthrough designation, and orphan drug designation. FDA expedited programs are described in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics. Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 1-800-FDA-1088. For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov. Follow the Oncology Center of Excellence on X: @FDAOncology. Content current as of: 10/29/2024 Regulated Product(s) Drugs Oncology